These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2975551)

  • 1. The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption.
    Ziel FH; Davidson MB; Harris MD; Rosenberg CS
    Diabet Med; 1988 Oct; 5(7):662-6. PubMed ID: 2975551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
    Heinemann L; Klappoth W; Rave K; Hompesch B; Linkeschowa R; Heise T
    Diabetes Care; 2000 Sep; 23(9):1343-7. PubMed ID: 10977030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin.
    Heinemann L; Chantelau EA; Starke AA
    Diabete Metab; 1992; 18(1):21-4. PubMed ID: 1563532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
    Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
    Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional and sprinkler needle injection of magnesium insulin.
    Colagiuri S; Bryson J; Keating S; Tan L; King J; Eigenmann C; Jørgensen KH
    Diabet Med; 1992; 9(7):616-21. PubMed ID: 1511567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of insulin-induced hypoglycaemia on absorption of unmodified insulin after subcutaneous or intramuscular injection.
    Grønlund B; Frandsen H; Lauritzen M; Nielsen SL; Madsbad S
    Diabet Med; 1991 Jan; 8(1):13-7. PubMed ID: 1826237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action profiles of fast onset insulin analogues.
    Heinemann L; Starke AA; Heding L; Jensen I; Berger M
    Diabetologia; 1990 Jun; 33(6):384-6. PubMed ID: 2199281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action profile of the rapid acting insulin analogue: human insulin B28Asp.
    Heinemann L; Heise T; Jorgensen LN; Starke AA
    Diabet Med; 1993 Jul; 10(6):535-9. PubMed ID: 8365089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.
    ter Braak EW; Woodworth JR; Bianchi R; Cerimele B; Erkelens DW; Thijssen JH; Kurtz D
    Diabetes Care; 1996 Dec; 19(12):1437-40. PubMed ID: 8941480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
    Heinemann L; Weyer C; Rauhaus M; Heinrichs S; Heise T
    Diabetes Care; 1998 Nov; 21(11):1910-4. PubMed ID: 9802742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-action profile of inhaled insulin.
    Heinemann L; Traut T; Heise T
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous insulin infusion to simulate subcutaneous absorption. Bioavailability and metabolic sequelae.
    Watanabe RM; Vølund A; Bergman RN
    Diabetes Care; 1991 Nov; 14(11):1021-30. PubMed ID: 1797482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
    Hildebrandt P
    Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response relationship of oral insulin spray in healthy subjects.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Diabetes Care; 2005 Jun; 28(6):1353-7. PubMed ID: 15920051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.